NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
UMIN ID: UMIN000032637

Registered date:01/06/2018

Prospective study for effectiveness of Etelcalcetide hydrochloride (Parsabiv) on patients treated with hemodialysis

Basic Information

Recruitment status Pending
Health condition(s) or Problem(s) studiedpatients treated with hemodialysis
Date of first enrollment2018/06/01
Target sample size200
Countries of recruitmentJapan
Study typeObservational
Intervention(s)

Outcome(s)

Primary OutcomeChange of QOL (every month)
Secondary OutcomeEstimation od complication (every month) CTR/ECG (every month) bone mineral density and UCG(1 year later) General blood test (every month) Check of leftover medicine

Key inclusion & exclusion criteria

Age minimum20years-old
Age maximum80years-old
GenderMale and Female
Include criteria
Exclude criteriaPatients decided as incompetent for this study by the doctor Patietns showing contraindication for PARSABIV Patients showing low Ca(<8.4) before admonistration of PARSABIV Patients having malignant diseases Patients having serious diseases in liver, kidney (other than CRF), and heart. Patients treated with cinacalcet or bisphosphonate

Related Information

Contact

public contact
Name Ashio Yoshimura
Address ShinyokohamaChitosekannkoBLG 8F,3-6-4 Shinyokohama,kouhoku-ku,Yokohama Japan 222-0033
Telephone 045-477-3412
E-mail shinyokohd@gmail.com
Affiliation Zenjinkai Shinyokohama Daiichi Clinic Division of Nephrology
scientific contact
Name Ashio Yoshimura
Address ShinyokohamaChitosekannkoBLG 8F,3-6-4 Shinyokohama,kouhoku-ku,Yokohama Japan
Telephone 045-477-3412
E-mail shinyokohd@gmail.com
Affiliation Zenjinkai Shinyokohama Daiichi Clinic Division of Nephrology